Incyte and Genesis will leverage Genesis’ GEMS artificial intelligence (AI) platform to unlock the discovery of breakthrough ...

“Partnering with Genesis Therapeutics presents a unique opportunity to leverage their AI technologies to accelerate the ...

Incyte and Genesis Therapeutics have entered a strategic partnership aimed at the research, discovery and development of new ...

US biopharma Incyte and privately-held AI-focused biotech Genesis Therapeutics have entered into a strategic collaboration ...

Incyte (INCY) and Genesis Therapeutics announced that the companies have entered into a strategic collaboration focused on the research, ...

Incyte and Genesis Therapeutics have agreed to discover and optimize at least two initial small molecule compounds through Genesis’s AI platform, Genesis Exploration of Molecular Space (GEMS).

(RTTNews) - Thursday, Incyte Corp. (INCY) and Genesis Therapeutics have entered into a strategic partnership focused on the research, discovery, and development of small molecule medicines.

WILMINGTON, Del. & BURLINGAME, Calif. - Incyte (NASDAQ:INCY), a global biopharmaceutical company, has entered a strategic collaboration with Genesis Therapeutics, Inc., a pioneer in artificial ...

GEMS (Genesis Exploration of Molecular Space), the partnership will pursue the discovery and optimization of small molecule compounds for the collaboration targets. Incyte is granted exclusive ...

Incyte and Genesis will leverage Genesis’ GEMS artificial intelligence (AI) platform to unlock the discovery of breakthrough small molecule therapeutics against Incyte-selected targets Incyte ...